Related Experiment Video
Updated: Jul 7, 2026

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
Published on: July 26, 2017
TLR4 signaling mediates inflammation and tissue injury in nephrotoxicity
Binzhi Zhang1, Ganesan Ramesh, Satoshi Uematsu
1Division of Nephrology, Penn State University College of Medicine, Hershey, Pennsylvania 17033, USA.
Abstract:
The molecular mechanisms of acute kidney injury (AKI) remain unclear. Toll-like receptors (TLRs), widely expressed on leukocytes and kidney epithelial cells, regulate innate and adaptive immune responses. The present study examined the role of TLR signaling in cisplatin-induced AKI. Cisplatin-treated wild-type mice had significantly more renal dysfunction, histologic damage, and leukocytes infiltrating the kidney than similarly treated mice with a targeted deletion of TLR4 [Tlr4(-/-)]. Levels of cytokines in serum, kidney, and urine were increased significantly in cisplatin-treated wild-type mice compared with saline-treated wild-type mice and cisplatin-treated Tlr4(-/-) mice. Activation of JNK and p38, which was associated with cisplatin-induced renal injury in wild-type mice, was significantly blunted in Tlr4(-/-) mice. Using bone marrow chimeric mice, it was determined that renal parenchymal TLR4, rather than myeloid TLR4, mediated the nephrotoxic effects of cisplatin. Therefore, activation of TLR4 on renal parenchymal cells may activate p38 MAPK pathways, leading to increased production of inflammatory cytokines, such as TNF-alpha and subsequent kidney injury. Targeting the TLR4 signaling pathways may be a feasible therapeutic strategy to prevent cisplatin-induced AKI in humans.
Insights
Toll-like receptor 4 (TLR4) signaling in kidney cells exacerbates cisplatin-induced acute kidney injury (AKI). Blocking TLR4 activation may offer a new therapeutic approach for preventing kidney damage from chemotherapy.
Area of Science:
- Nephrology
- Immunology
- Molecular Biology
Background:
- Acute kidney injury (AKI) mechanisms are not fully understood.
- Toll-like receptors (TLRs) are key regulators of immune responses.
- The role of TLR signaling in cisplatin-induced AKI requires further investigation.
Purpose of the Study:
- To investigate the role of Toll-like receptor 4 (TLR4) signaling in cisplatin-induced acute kidney injury (AKI).
Main Methods:
- Compared cisplatin-treated wild-type mice with Tlr4(-/-) knockout mice.
- Measured renal dysfunction, kidney damage, and immune cell infiltration.
- Analyzed cytokine levels and activation of JNK and p38 signaling pathways.
- Utilized bone marrow chimeric mice to differentiate between myeloid and parenchymal TLR4 roles.
Main Results:
- Tlr4(-/-) mice exhibited significantly less renal dysfunction, histologic damage, and leukocyte infiltration after cisplatin treatment compared to wild-type mice.
- Cytokine levels were elevated in cisplatin-treated wild-type mice but not in Tlr4(-/-) mice.
- Activation of JNK and p38 pathways, linked to renal injury, was reduced in Tlr4(-/-) mice.
- Renal parenchymal TLR4, not myeloid TLR4, was identified as the mediator of cisplatin nephrotoxicity.
Conclusions:
- TLR4 activation on renal parenchymal cells contributes to cisplatin-induced AKI by activating p38 MAPK pathways and increasing inflammatory cytokine production.
- Targeting TLR4 signaling pathways presents a potential therapeutic strategy for preventing cisplatin-induced AKI.
Related Concept Videos
Acute Inflammation III: Local and Systemic Effects
Acute Kidney Injury II: Pathophysiology
Inflammatory Response
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Inflammation I: Inflammatory Response
Chronic Inflammation: Introduction
